When the cyclic AMP (cAMP) concentration in platelets is increased, platelet functions
are inhibited. It is generally assumed that inhibitors of cAMP phosphodiesterase inhibit
platelet reactions by increasing cAMP, but this is not established. We have studied
the effects of cAMP phosphodiesterase inhibitors on ADP-induced platelet shape change,
nucleoside diphosphokinase (NDK) activity, and cAMP concentrations. Papaverine (0.08
mM), dipyridamole (0.2 mM), caffeine (10 mM), or theophylline (8 mM) prevented the
shape change of washed rabbit platelets induced by 1 μM ADP. We showed previously
that PGEi, which increases cAMP, inhibits platelet NDK activity. Therefore we investigated
the effects of cAMP phosphodiesterase inhibitors on platelet NDK activity and cAMP.
At concentrations that prevented ADP-induced shape change, papaverine and dipyridamole
had no effect on the formation of 14C-ATP from 14C-ADP by washed rabbit platelets. The methylxanthines partially inhibited NDK activity
of washed rabbit platelets and of isolated membranes, probably due to the structural
similarity between the adenine ring of ADP and these substances. However, it seems
unlikely that these substances exert their inhibitory effects through interference
with platelet NDK. None of these phosphodiesterase inhibitors increased platelet cAMP
above basal levels, measured both by a protein binding assay and by prelabeling the
platelet adenine nucleotides by incubation with 14C-adenine. When adenylate cyclase was stimulated with PGE1 (1.2 μM), the cAMP concentration was increased from 7.8 to 27.2 pmol/108 platelets, and in the presence of phosphodiesterase inhibitors,the cAMP concentration
was greater than 50 pmol/108 platelets at 90 sec. Since the phosphodiesterase inhibitors by themselves had no
detectable effect on cAMP at concentrations that inhibit ADP-induced shape change,
it seems likely that they act through other mechanisms. Whether or not they all act
in the same way remains to be determined.